Clinical pathways provide opportunities to facilitate a shift towards patients who have ownership of their treatment and behave as active consumers.
Dr Mckenna looks at how patient-reported outcome measures have been used in oncology and how they can be better utilized to improve patient outcomes.
Yoram Unguru, MD, MS, MA addresses the pervasive problem of drug shortages in cancer care and what is being done to resolve the issue. 
Edward J Stepanski discusses the underlying tension between payers and providers with respect to the aims of clinical pathways and the recent policy statement released by the American Society of Clinical Oncology. 
Roger Longman, MA, offers a perspective on how we can overcome comparative effectiveness research and bring a greater understanding on which drugs work best. 
The debate continues to rage over the current cost of cancer care and the value that these drugs bring to patients.